Advertisement

Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy

  • Yan Li
  • Musaddiq J. AwanEmail author
  • Tangel Chang
  • Pierre Lavertu
  • Chad Zender
  • Rod Rezaee
  • Nicole Fowler
  • Jay Wasman
  • Norbert E. Avril
  • Nianyong Chen
  • Mitchell Machtay
  • Min Yao
Original Article
  • 181 Downloads

Abstract

Purpose

The purpose of this study was to retrospectively review the role of post-treatment (post-tx) FDG-PET/CT scans in patients receiving postoperative intensity-modulated radiotherapy (IMRT) for head and neck squamous cell carcinomas (HNSCC).

Materials and methods

Eighty-two patients with HNSCC treated with surgery and postoperative IMRT with or without chemotherapy from October 15, 2008 to December 31, 2014 that had post-tx PET/CT within 6 months of completing IMRT were included. PET/CT was considered positive based on multi-disciplinary review integrating clinical information. Survival analysis was performed using the Kaplan-Meier method. Categorical and continuous predictors of positive post-tx PET/CT were evaluated using Fisher’s exact test and logistic regression, respectively. Predictors for survival outcomes were evaluated with log-rank testing. A p ≤ 0.05 was considered statistically significant.

Results

Median follow-up was 3.88 years. For all patients, 3-year overall survival (OS) and recurrence-free survival (RFS) were 71.8% and 61.3%, respectively. Patients with positive post-tx PET/CT had worse OS compared to those with negative post-tx PET/CT (log rank p < 0.001). For patients with positive post-tx PET/CT, 3-year OS was 11.2% compared to 89.9% for patients with negative post-tx PET/CT. The positive predictive value (PPV) of PET/CT was 100% for local recurrence (LR), regional recurrence (RR) and distant metastasis (DM). The negative predictive values (NPV) for LR, RR and DM were 89.0%, 89.2%, and 85.9%, respectively. Perineural invasion (p = 0.009), p16 status (p = 0.009), non-oropharyngeal primary site (p = 0.002), and the use of chemotherapy (p = 0.01) were independent predictors of positive PET/CT.

Conclusions

Post-tx PET/CT after postoperative radiation is prognostic for survival outcomes. The PPV of post-tx PET for recurrence was excellent, allowing for early detection of recurrent disease. Post-tx PET/CT should be considered after postoperative radiation.

Keywords

Head and neck cancer PET/CT Prognostic factors Postoperative radiotherapy 

Notes

Compliance with ethical standards

Conflict of interest

Yan Li MD has no conflicts of interest. Musaddiq J. Awan MD has no conflicts of interest. Tangel Chang D.O. has no conflicts of interest. Pierre Lavertu MD has no conflicts of interest. Chad Zender MD has no conflicts of interest. Rod Rezaee MD has no conflicts of interest. Nicole Fowler MD has no conflicts of interest. Jay Wasman MD has no conflicts of interest. Norbert Avril, MD has no conflicts of interest. Nianyong Chen, MD PhD has no conflicts of interest. Mitchell Machtay MD reports that he is a consultant for Bristol-Myers, Abbvie and Novocure. Min Yao MD PhD has no conflicts of interest.

Ethical approval

This is a retrospective, minimal risk study. Institutional review board approval was obtained for retrospective review of patient charts. This was performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374:1444–54.  https://doi.org/10.1056/NEJMoa1514493.CrossRefGoogle Scholar
  2. 2.
    Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78:667–74.  https://doi.org/10.1016/j.ijrobp.2009.08.063.CrossRefGoogle Scholar
  3. 3.
    Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991–9.  https://doi.org/10.1016/j.ijrobp.2005.03.066.CrossRefGoogle Scholar
  4. 4.
    Yao M, Smith RB, Hoffman HT, Funk GF, Lu M, Menda Y, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9–14.  https://doi.org/10.1016/j.ijrobp.2008.07.019.CrossRefGoogle Scholar
  5. 5.
    Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004;60:1410–8.  https://doi.org/10.1016/j.ijrobp.2004.05.058.CrossRefGoogle Scholar
  6. 6.
    Hitchcock KE, Amdur RJ, Mendenhall WM, Werning JW, Drane WE, Mancuso AA. Lessons from a standardized program using PET-CT to avoid neck dissection after primary radiotherapy for N2 squamous cell carcinoma of the oropharynx. Oral Oncol. 2015;51:870–4.  https://doi.org/10.1016/j.oraloncology.2015.06.012.CrossRefGoogle Scholar
  7. 7.
    Goenka A, Morris LGT, Rao SS, Wolden SL, Wong RJ, Kraus DH, et al. Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer. Int J Cancer. 2013;133:1214–21.  https://doi.org/10.1002/ijc.28120.CrossRefGoogle Scholar
  8. 8.
    Chan JYK, Sanguineti G, Richmon JD, Marur S, Gourin CG, Koch W, et al. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138:1040–6.  https://doi.org/10.1001/jamaoto.2013.607.CrossRefGoogle Scholar
  9. 9.
    Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011;33:1675–82.  https://doi.org/10.1002/hed.21655.CrossRefGoogle Scholar
  10. 10.
    Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope. 2007;117:2129–34.  https://doi.org/10.1097/MLG.0b013e318149e6bc.CrossRefGoogle Scholar
  11. 11.
    Helsen N, Van den Wyngaert T, Carp L, Stroobants S. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. Eur J Nucl Med Mol Imaging. 2018;45(6):1063–71.  https://doi.org/10.1007/s00259-018-3978-3.CrossRefGoogle Scholar
  12. 12.
    Awan MJ, Lavertu P, Zender C, Rezaee R, Fowler N, Karapetyan L, et al. Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation. Eur J Nucl Med Mol Imaging. 2017;44:988–97.  https://doi.org/10.1007/s00259-016-3612-1.CrossRefGoogle Scholar
  13. 13.
    Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–95.  https://doi.org/10.1007/s00259-011-1893-y.CrossRefGoogle Scholar
  14. 14.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.  https://doi.org/10.1056/NEJMoa0802656.CrossRefGoogle Scholar
  15. 15.
    Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.  https://doi.org/10.1016/s1470-2045(16)30066-3.CrossRefGoogle Scholar
  16. 16.
    Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.  https://doi.org/10.1056/NEJMoa1602252.CrossRefGoogle Scholar
  17. 17.
    Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009;50:74S–88S.  https://doi.org/10.2967/jnumed.108.057208.CrossRefGoogle Scholar
  18. 18.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.  https://doi.org/10.1056/NEJMoa0912217.CrossRefGoogle Scholar
  19. 19.
    Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al. P16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014;32:3930–8.  https://doi.org/10.1200/JCO.2013.54.5228.CrossRefGoogle Scholar
  20. 20.
    Laske RD, Scholz I, Ikenberg K, Meerwein C, Vital DG, Studer G, et al. Perineural invasion in squamous cell carcinoma of the oral cavity: histology, tumor stage, and outcome. Laryngoscope Investig Otolaryngol. 2016;1:13–8.  https://doi.org/10.1002/lio2.4.CrossRefGoogle Scholar
  21. 21.
    Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571–8.CrossRefGoogle Scholar
  22. 22.
    Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.  https://doi.org/10.1002/hed.20279.CrossRefGoogle Scholar
  23. 23.
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.  https://doi.org/10.1056/NEJMoa032641.CrossRefGoogle Scholar
  24. 24.
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.  https://doi.org/10.1056/NEJMoa032646.CrossRefGoogle Scholar
  25. 25.
    Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:322–9.  https://doi.org/10.1016/j.ijrobp.2007.06.038.CrossRefGoogle Scholar
  26. 26.
    Liao C-T, Fan K-H, Lin C-Y, Wang H-M, Huang S-F, Chen I-H, et al. Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. Eur J Nucl Med Mol Imaging. 2012;39:944–55.  https://doi.org/10.1007/s00259-012-2103-2.CrossRefGoogle Scholar
  27. 27.
    Dutta PR, Riaz N, McBride S, Morris LG, Patel S, Ganly I, et al. Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. Head Neck. 2016;38:E1285–E93.  https://doi.org/10.1002/hed.24213.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yan Li
    • 1
  • Musaddiq J. Awan
    • 2
    Email author
  • Tangel Chang
    • 3
  • Pierre Lavertu
    • 4
  • Chad Zender
    • 4
  • Rod Rezaee
    • 4
  • Nicole Fowler
    • 4
  • Jay Wasman
    • 5
  • Norbert E. Avril
    • 6
  • Nianyong Chen
    • 1
  • Mitchell Machtay
    • 7
  • Min Yao
    • 7
  1. 1.Department of Radiation OncologyWest China Hospital of Sichuan UniversityChengduChina
  2. 2.Department of Radiation OncologyMedical College of WisconsinMilwaukeeUSA
  3. 3.Department of Radiation OncologyUniversity of ToledoToledoUSA
  4. 4.Department of Otolaryngology and Head and Neck SurgeryUniversity HospitalsClevelandUSA
  5. 5.Department of PathologyUniversity HospitalsClevelandUSA
  6. 6.Department of Nuclear Medicine and RadiologyUniversity HospitalsClevelandUSA
  7. 7.Department of Radiation OncologyCase Western Reserve University and University HospitalsClevelandUSA

Personalised recommendations